Le Lézard
Classified in: Tourism and vacations, Transportation, Health, Covid-19 virus
Subjects: PSF, CFG

Update #4: Statement from the Chief Public Health Officer on the release of selected individuals from quarantine for the 2019 novel coronavirus

OTTAWA, Feb. 15, 2020 /CNW/ - Further to my previous statements, as Chief Public Health Officer, I have assessed additional individuals in quarantine at Canadian Forces Base (CFB) Trenton pursuant to an Emergency Order under the Quarantine Act and determined that they do not pose a risk of significant harm to public health.

I have authorized the release of 23 flight crew members who accompanied the returning travellers on the second Canada-chartered flight from Wuhan to Vancouver to CFB Trenton. In my assessment, I took into account the fact that they did not spend time in the epicentre of the outbreak, that they followed appropriate infection prevention and control protocols (including the use of personal protective equipment), and that they did not have unprotected contact with passengers or persons at risk of having the novel coronavirus. As a result of this assessment, I have determined that their continued quarantine is not required.

SOURCE Public Health Agency of Canada

These press releases may also interest you

at 07:05
LifeMax Laboratories, Inc. ("LifeMax"), a private company focused on treating orphan diseases that have few or no therapeutic options, today announced the formation of AmMax Bio, Inc. ("AmMax") and an exclusive worldwide license from Amgen for the...

at 07:05
AstraZeneca today announced that IMFINZI® (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care (SoC) chemotherapies, etoposide...

at 07:05
ElevateBio, LLC, a Cambridge-based creator and operator of a portfolio of innovative cell and gene therapy companies, today announced it has closed a $170-million Series B financing that will support and accelerate the company's next phase of growth....

at 07:05
Generation Bio and Vir Biotechnology today announced a collaborative research agreement to explore the potential for Generation Bio's non-viral gene therapy platform to extend the impact and reach of Vir's current or future human monoclonal...

at 07:05
Compass Therapeutics, a clinical-stage biotechnology company focused on drugging the human immune synapse, today announced the publication of extensive data demonstrating the preclinical efficacy and safety of the company's lead investigational...

at 07:05
Seres Therapeutics, Inc., announced today that the Company has completed enrollment of its SER-109 Phase 3 clinical study, ECOSPOR III. SER-109 is an oral, first-in-field microbiome therapeutic candidate that has been granted Orphan Drug and...

News published on 15 february 2020 at 21:03 and distributed by: